Dendritic cell vaccine - Medigene

Drug Profile

Dendritic cell vaccine - Medigene

Alternative Names: DC vaccine - Medigene Immunotherapies; IL-12p70 DC vaccine; Leukemia-associated RNA transfected autologous dendritic cell vaccine - Medigene Immunotherapies; PRAME-mRNA-transfected dendritic cell vaccines - Medigene Immunotherapies; TLR-7/8-polarised dendritic cell vaccines - Medigene Immunotherapies; WT1-mRNA-transfected dendritic cell vaccines - Medigene Immunotherapies

Latest Information Update: 19 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Trianta Immunotherapies
  • Developer Ludwig-Maximilians-University; Medigene Immunotherapies; University of Oslo
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants; Natural killer cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Prostate cancer

Most Recent Events

  • 17 Apr 2018 Updated efficacy data from a phase II trial in Prostate cancer presented at American Association for Cancer Research (AACR-2018)
  • 27 Nov 2017 Medigene completes enrolment in a phase I/II trial for Acute myeloid leukaemia in Norway (NCT02405338)
  • 04 Apr 2017 Efficacy data from a compassionate-use study in Acute myeloid leukaemia presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top